CTOs on the Move

AMAG Pharmaceuticals

www.amagpharma.com

 
AMAG is a biopharmaceutical company focused on bringing therapeutics to market that provide clear benefits and help improve people’s lives. Headquartered in Waltham, Massachusetts, we work to develop and deliver important therapeutics, conduct clinical research in areas of unmet need and create education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Brad Dutot
 Executive Director, Enterprise Architecture Profile
Mark Begley
 Senior Director, Commercial Technology Profile

Similar Companies

G-Biosciences/ Genotech

G-Biosciences/ Genotech is a Maryland Heights, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BGI Americas Corporation

BGI Americas Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeoPharm

NeoPharm, Inc. is a Waukegan, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Center for Breakthrough Medicines

The Center for Breakthrough Medicines is the Worlds Largest and Most Advanced Single Solution Cell and Gene Therapy Contract Development and Manufacturing Organization. Period.

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).